

A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries

NCT07251933

Status RECRUITING
Sponsor Takeda
Enrollment 40 participants

Key Eligibility Criteria

Inclusion (5)

- Participant is aged 2 to less than (<) 12 years at the time of lanadelumab initiation and is expected to have at least 6 months of follow-up information before turning 12.
- Participant has physician-confirmed diagnosis of HAE-C1INH.
- Participant initiated LTP with lanadelumab during the eligibility period.
- Signed consent/assent (where required by local regulations).
- Participant's medical record contains documentation of HAE attacks in the pre-index period and after lanadelumab initiation.

Exclusion (2)

- Participant was enrolled in a therapeutic investigational drug (lanadelumab or other drug) or device trial at index date.
- Participant with no documented HAE attacks in the 12 months prior to index date.

Locations (24 total)

Hospital de Ninos Sor Maria Ludovica, La Plata, Buenos Aires, Argentina
Centro de Alergia e Inmunologia Clinica Mar del Plata, Mar del Plata, Buenos Aires, Argentina
Hospital de Pediatria S.A.M.I.C.- Prof. Dr. Juan P. Garrahan, Ciudad de Buenos Aires, Buenos Aires F.D., Argentina
... and 21 more locations